On the morning of October 27, delegation from the General Administration of Customs conducted an inspection tour on the development of the biomedical industry in the China (Jiangsu) Pilot Free Trade Zone Nanjing Area, joined by member of the Party Working Committee and Deputy Director of the Administrative Committee of Jiangbei New Area Lin Qikun, Secretary of the Party Working Committee and Director of Life and Health Industrial Development Management Office Chen Hong, Analyst at level 2 of Nanjing Customs Ke Jiafa, Deputy Director of Nanjing Customs Gu Zhijun, Deputy Commissioner of Jinling Customs Wan Qiang and other leaders.

With focus on the biomedicine public service platform of the Jiangbei New Area, experts visited the Big Data Center, DNA-Sequencing Center, Mass Spectrometry Detection and Analysis Center, and Biological Sample Center. According to the development plan, the National Health and Medical Big Data (Eastern) Center will be responsible for the storage, analysis and application of the big data in clinical medicine, public health, and life sciences of 300 to 400 million people in eastern China and build a big data platform of population health information for eastern China.

Experts of the General Administration of Customs then held a meeting to hear work reports from local governments and customs, with focus on the reform measures for the quarantine and supervision of imported biological materials of animal origin in the Nanjing Area.

This year, with the support of the Jinling Customs, a centralized supervision and public service platform for the import and export of biomedicine of the Jiangbei New Area was established, bringing forth a fast examination channel for biological special items. As one of the top 10 pilot cases of national service trade innovation, this innovative measure greatly facilitates the development of enterprises in the Jiangbei New Area (Pilot Free Trade Zone).

Chen Hong mainly reported on the development of the life and health industry and the achievements of the centralized supervision and public service platform for import and export of biomedicine of the Jiangbei New Area since its establishment.

In the next stage, Jiangbei New Area (Pilot Free Trade Zone) will further improve its services, accelerate product development and industrialization in key areas such as precision medicine, innovative drug technology, process research and development, and high-end medical devices, and cultivate stronger, better and more specialized large-scale enterprises and high-growth enterprises as pacesetters, promote the development of characteristic industries such as biomedicine, high-end medical equipment, genetic testing, raw and auxiliary materials, and general health, and create a high-end, international and market-oriented life and health industrial chain with distinctive features.